98%
921
2 minutes
20
Mutations in atrial-enriched genes can cause a primary atrial myopathy that can contribute to overall cardiovascular dysfunction. encodes myosin-binding protein H-like (MyBP-HL), an atrial sarcomere protein that shares domain homology with the carboxy-terminus of cardiac myosin-binding protein-C (cMyBP-C). The function of MyBP-HL and the relationship between MyBP-HL and cMyBP-C is unknown. To decipher the roles of MyBP-HL, we used structured illumination microscopy, immuno-electron microscopy, and mass spectrometry to establish the localization and stoichiometry of MyBP-HL. We found levels of cMyBP-C, a major regulator of myosin function, were half as abundant compared to levels in the ventricle. In genetic mouse models, loss of MyBP-HL doubled cMyBP-C abundance in the atria, and loss of cMyBP-C doubled MyBP-HL abundance in the atria. Structured illumination microscopy showed that both proteins colocalize in the C-zone of the A-band, with MyBP-HL enriched closer to the M-line. Immuno-electron microscopy of mouse atria showed MyBP-HL strongly localized 161 nm from the M-line, consistent with localization to the third 43 nm repeat of myosin heads. Both cMyBP-C and MyBP-HL had less-defined sarcomere localization in the atria compared to ventricle, yet areas with the expected 43 nm repeat distance were observed for both proteins. Isometric force measurements taken from control and null single atrial myofibrils revealed that loss of accelerated the linear phase of relaxation. These findings support a mechanism where MyBP-HL regulates cMyBP-C abundance to alter the kinetics of sarcomere relaxation in atrial sarcomeres.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10741380 | PMC |
http://dx.doi.org/10.1073/pnas.2314920120 | DOI Listing |
Sci Rep
August 2025
Department of Cardiology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
While cardiac myosin-binding protein-C (cMyBP-C) is a promising biomarker for acute coronary syndrome, its clinical utility in stable coronary artery disease (CAD) remains poorly defined. To investigate the association of cMyBP-C with the presence and angiographic severity of stable CAD, and to evaluate its prognostic value for 1-year major adverse cardiovascular events (MACEs). This study enrolled 367 patients undergoing coronary angiography for suspected CAD.
View Article and Find Full Text PDFRapid Commun Mass Spectrom
December 2025
Leicester van Geest MultiOMICs Facility, University of Leicester, Leicester, UK.
Rationale: Molecular imprinting has emerged as a promising strategy to create custom imprints for precision recognition of proteins. This study proposes using dopamine polymers as a novel approach to enhance the retrieval of proteins from human plasma. Dopamine polymers possess adhesive properties due to their ability to form hydrophobic interactions, π-π, hydrogen bonding and van der Waals forces with various substrates; in this study, we have leveraged these adhesive properties to capture and retrieve proteins from complex biological samples.
View Article and Find Full Text PDFJ Gen Physiol
November 2025
Department of Molecular Physiology and Biophysics, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Cardiac contractility is driven by shortening of ∼2-μm-long, macromolecular assemblies known as sarcomeres. During contraction, the motor protein myosin binds to, and exerts force upon actin filaments, utilizing energy from the hydrolysis of ATP. When not actively contracting, myosin partition into two subpopulations, distinguished by their basal rates of ATP hydrolysis, known as the "Disordered Relaxed" (DRX) and "Super Relaxed" (SRX) states.
View Article and Find Full Text PDFAnn Med Surg (Lond)
July 2025
Department of Research, Medical Research Circle (MedReC), Goma, DR Congo.
Background: Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disorder characterized by unexplained left ventricular hypertrophy, affecting approximately 0.2% of the global population. Around 40% of HCM cases are linked to mutations in sarcomeric protein genes such as β-myosin heavy chain and myosin-binding protein C, which impair calcium signaling and myocardial contractility.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
August 2025
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110.
Heart failure is a leading cause of death worldwide, and even with current treatments, the 5-y transplant-free survival rate is only ~50 to 70%. As such, there is a need to develop new treatments for patients that improve survival and quality of life. Recently, there have been efforts to develop small molecules for heart failure that directly target components of the sarcomere, including cardiac myosin.
View Article and Find Full Text PDF